Preoperative alpha-adrenergic blockade (phenoxybenzamine, before pheochromocytoma/paraganglioma surgery)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Composantes | DRUG-PHENOXYBENZAMINE |
|---|
| ID | REG-ALPHA-BLOCKADE-PREOP-PHEO |
|---|---|
| Type | Protocole thérapeutique |
| État | reviewed 2026-07-11 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-ENDOCRINE-SOCIETY-PPGL-2014 SRC-NCCN-NET-2025 |
Notes
This regimen models the mandatory preoperative alpha-adrenergic blockade step described in the Disease narrative -- NOT a cytotoxic or antineoplastic regimen. It is the recommended_regimen on IND-PHEO-LOCALIZED-1L-ALPHA-BLOCKADE-ADRENALECTOMY and exists purely to prevent intraoperative catecholamine-release hypertensive crisis during adrenalectomy. Adequacy of blockade is gated by RF-PHEO-INADEQUATE-ALPHA-BLOCKADE, a hard hold on proceeding to surgery. No fixed target BP/HR numeric threshold is asserted here -- "adequate" blockade is a clinical judgment per Endocrine Society 2014 guidance, not a KB-invented number. STUB pending clinical co-lead signoff (CHARTER §6.1, dev-mode-exempted).
Utilisé par
Indication
IND-PHEO-LOCALIZED-1L-ALPHA-BLOCKADE-ADRENALECTOMY- IND-PHEO-LOCALIZED-1L-ALPHA-BLOCKADE-ADRENALECTOMY